Free Trial
Discover Investing Tools for the A.I EraStart My Trial

Takeda Pharmaceutical (TAK) Stock Forecast & Price Target

Takeda Pharmaceutical logo
$13.72 +0.02 (+0.11%)
As of 03:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare

Takeda Pharmaceutical - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold
Based on 3 Analyst Ratings
Sell
1
Hold
1
Buy
1

Based on 3 Wall Street analysts who have issued ratings for Takeda Pharmaceutical in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 1 has given a sell rating, 1 has given a hold rating, and 1 has given a buy rating for TAK.

Consensus Price Target

N/A

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for TAK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Takeda Pharmaceutical and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TAK Analyst Ratings Over Time

TypeCurrent Forecast
10/13/24 to 10/13/25		1 Month Ago
9/13/24 to 9/13/25		3 Months Ago
7/15/24 to 7/15/25		1 Year Ago
10/14/23 to 10/13/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
 N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
 N/A
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
 N/A
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
 N/A
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus RatingHoldHoldBuyN/A

TAK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TAK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Takeda Pharmaceutical Stock vs. The Competition

TypeTakeda PharmaceuticalMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.33
2.52
Consensus RatingHoldHoldModerate Buy
Predicted UpsideN/A1,027.07% Upside176.40% Upside
News Sentiment Rating
Positive News

See Recent TAK News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
9/27/2025Weiss Ratings
0 of 5 stars		 Reiterated RatingHold (C)
8/21/2025Zacks Research
0 of 5 stars		 DowngradeHold ➝ Strong Sell
4/2/2025Morgan Stanley
3 of 5 stars		 UpgradeEqual Weight ➝ Overweight

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:54 PM ET.


Should I Buy Takeda Pharmaceutical Stock? TAK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 10, 2025. Please send any questions or comments about these Takeda Pharmaceutical pros and cons to contact@marketbeat.com.

Takeda Pharmaceutical
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Takeda Pharmaceutical Company Limited:

  • The current stock price recently reached a new 52-week high, indicating strong market performance and investor confidence.
  • Takeda Pharmaceutical Company Limited reported earnings per share (EPS) of $0.52, surpassing analyst expectations, which reflects effective management and operational efficiency.
  • The company has a solid market capitalization of approximately $48 billion, suggesting a stable financial foundation and potential for growth.
  • Recent upgrades from analysts, including a Buy rating from one investment analyst, indicate positive sentiment and potential for future stock appreciation.
  • Takeda Pharmaceutical Company Limited has a diversified portfolio and is actively engaged in research and development, which can lead to innovative products and revenue growth.

Takeda Pharmaceutical
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Takeda Pharmaceutical Company Limited for these reasons:

  • Zacks Research recently downgraded the stock from a "hold" rating to a "strong sell" rating, indicating concerns about the company's future performance.
  • The company reported revenue of $7.45 billion, which fell short of analyst expectations, suggesting potential challenges in meeting market demands.
  • Takeda Pharmaceutical Company Limited has a relatively high P/E ratio, which may indicate that the stock is overvalued compared to its earnings.
  • With a quick ratio of 0.59, the company may face liquidity issues, which could impact its ability to cover short-term obligations.
  • Market volatility and economic uncertainties could pose risks to the pharmaceutical sector, affecting Takeda's stock performance.

TAK Forecast - Frequently Asked Questions

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last year. There is currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TAK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.

According to analysts, Takeda Pharmaceutical's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Takeda Pharmaceutical's stock had 1 downgrade by analysts.

Takeda Pharmaceutical has been rated by research analysts at Weiss Ratings, and Zacks Research in the past 90 days.

Analysts like Takeda Pharmaceutical less than other "medical" companies. The consensus rating score for Takeda Pharmaceutical is 2.00 while the average consensus rating score for "medical" companies is 2.33. Learn more on how TAK compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:TAK) was last updated on 10/13/2025 by MarketBeat.com Staff
From Our Partners
URGENT: The Market's 3 Red Flags Are Flashing
Here’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...
StockEarnings | Sponsoredtc pixel
Bitcoin grabs headlines, but smart money likes this token
Bitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...
Crypto 101 Media | Sponsoredtc pixel
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...
Priority Gold | Sponsoredtc pixel
Capital Gains Tax Strategies for Seniors
Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...
SmartAsset | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
2013 miner reveals his trading system
While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...
Crypto Swap Profits | Sponsoredtc pixel
Gold surges past $3,600 … but this has beat gold by 1,000x
Gold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...
Weiss Ratings | Sponsoredtc pixel
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...
Angel Publishing | Sponsoredtc pixel